Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Cresco Labs (CRLBF) over the last 7 years, with Q3 2025 value amounting to $940.2 million.

  • Cresco Labs' Total Liabilities fell 760.62% to $940.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $940.2 million, marking a year-over-year decrease of 760.62%. This contributed to the annual value of $967.2 million for FY2024, which is 395.3% up from last year.
  • Latest data reveals that Cresco Labs reported Total Liabilities of $940.2 million as of Q3 2025, which was down 760.62% from $986.8 million recorded in Q2 2025.
  • Over the past 5 years, Cresco Labs' Total Liabilities peaked at $1.0 billion during Q1 2022, and registered a low of $696.8 million during Q1 2021.
  • Moreover, its 5-year median value for Total Liabilities was $978.0 million (2021), whereas its average is $951.8 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 20417.3% in 2021, then plummeted by 760.62% in 2025.
  • Over the past 5 years, Cresco Labs' Total Liabilities (Quarter) stood at $982.7 million in 2021, then rose by 1.35% to $996.0 million in 2022, then decreased by 6.59% to $930.4 million in 2023, then rose by 3.95% to $967.2 million in 2024, then decreased by 2.79% to $940.2 million in 2025.
  • Its Total Liabilities was $940.2 million in Q3 2025, compared to $986.8 million in Q2 2025 and $988.5 million in Q1 2025.